Etiketter

onsdag 27 maj 2015

ISBT 023 , MMPs reseptori CD44 on Indian veriryhmän antigeenin kantajamolekyyli.

CD44

From Wikipedia, the free encyclopedia
(Redirected from CSPG8)
Jump to: navigation, search
edit
CD44 molecule (Indian blood group)

PDB rendering based on 1poz.
Identifiers
Symbols CD44; CDW44; CSPG8; ECMR-III; HCELL; IN; LHR; MC56; MDU2; MDU3; MGC10468; MIC4; MUTCH-I; Pgp1
External IDs OMIM: 107269 MGI: 88338 HomoloGene: 508 GeneCards: CD44 Gene
RNA expression pattern
PBB GE CD44 204490 s at tn.png
PBB GE CD44 212063 at tn.png
PBB GE CD44 204489 s at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 960 12505
Ensembl ENSG00000026508 ENSMUSG00000005087
UniProt P16070 P15379
RefSeq (mRNA) NM_000610 NM_001039150
RefSeq (protein) NP_000601 NP_001034239
Location (UCSC) Chr 11:
35.12 - 35.21 Mb
Chr 2:
102.61 - 102.7 Mb

PubMed search [1] [2]
The CD44 antigen is a cell-surface glycoprotein involved in cell-cell interactions, cell adhesion and migration. In humans, the CD44 antigen is encoded by the CD44 gene.[1]

Contents

[hide]

Tissue distribution and isoforms

CD44 is expressed in a large number of mammalian cell types. The standard isoform, designated CD44s, comprising exons 1–5 and 16–20 is expressed in most cell types. CD44 splice variants containing variable exons are designated CD44v. Some epithelial cells also express a larger isoform (CD44E), which includes exons v8–10.[2]

Function

CD44 is a receptor for hyaluronic acid and can also interact with other ligands, such as osteopontin, collagens, and matrix metalloproteinases (MMPs). CD44 function is controlled by its posttranslational modifications. One critical modification involves discrete sialofucosylations rendering the selectin-binding glycoform of CD44 called HCELL (for Hematopoietic Cell E-selectin/L-selectin Ligand). The HCELL glycoform was originally discovered on human hematopoietic stem cells and leukemic blasts,[3][4][5][6] and was subsequently identified on cancer cells.[7][8][9][10][11] HCELL functions as a "bone homing receptor", directing migration of human hematopoietic stem cells and mesenchymal stem cells to bone marrow.[5] Ex vivo glycan engineering of the surface of live cells has been used to enforce HCELL expression on any cell that expresses CD44.[12] CD44 glycosylation also directly controls its binding capacity to fibrin and immobilized fibrinogen.[13][14]
This protein participates in a wide variety of cellular functions including lymphocyte activation, recirculation and homing, hematopoiesis, and tumor metastasis. Transcripts for this gene undergo complex alternative splicing that results in many functionally distinct isoforms, however, the full length nature of some of these variants has not been determined. Alternative splicing is the basis for the structural and functional diversity of this protein, and may be related to tumor metastasis. Splice variants of CD44 on colon cancer cells display sialofucosylated HCELL glycoforms that serve as P-, L-, and E-selectin ligands and fibrin, but not fibrinogen, receptors under hemodynamic flow conditions pertinent to the process of cancer metastasis. CD44 gene transcription is at least in part activated by beta-catenin and Wnt signalling (also linked to tumour development).

Clinical significance

The protein is a determinant for the Indian blood group system. ISBT 023
  • CD44, along with CD25, is used to track early T cell development in the thymus.
  • CD44 expression is an indicative marker for effector-memory T-cells. Memory cell proliferation (activation) can also be assayed in vitro with CFSE chemical tagging.
In addition, variations in CD44 are reported as cell surface markers for some breast and prostate cancer stem cells.[15] and has been seen as an indicator of increased survival time in epithelial ovarian cancer patients.[16]
Endometrial cells in women with endometriosis demonstrate increased expression of splice variants of CD44, and increased adherence to peritoneal cells.[17]
CD44 variant isoforms are also relevant to the progression of head and neck squamous cell carcinoma.[18][19]
Monoclonal antibodies against CD44 variants include bivatuzumab for v6.

 Interactions

CD44 has been shown to interact with:

Inga kommentarer:

Skicka en kommentar